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Diffuse alveolar hemorrhage (DAH) from systemic lupus erythematosus (SLE) is a rare but potentially life-threatening
condition. We report the case of a 14-year-old female with SLE who developed hypoxia and shock secondary to severe
alveolar hemorrhage. She was successfully managed by placement on extracorporeal membrane oxygenation (ECMO)
followed by emergent pulmonary lobectomy and medical treatment including high-dose methylprednisolone,
cyclophosphamide, intravenous immunoglobulin, and plasmapheresis.
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A recent report of seven cases of pediatric systemic lupus
erythematosus (SLE) with pulmonary hemorrhage had a
survival rate of 87.5% [1]; however, the survival rate for
diffuse alveolar hemorrhage (DAH) is extremely low when
it leads to acute catastrophic hemoptysis with impairment
in oxygenation, ventilation, or hemodynamic instability. In
adults, high Acute Physiology and Chronic Health Evalu-
ation II scores, requirement of mechanical ventilation,
renal failure, and thrombocytopenia are associated with
higher mortality in DAH with SLE [2]. Despite recent ad-
vances in therapy, mortality in adults has not improved
(48% overall survival versus 53% survival in reports pub-
lished since 1993) using conventional therapies [3]. We
experienced a pediatric patient recently diagnosed with
SLE presenting in a critically ill condition due to DAH in
hypoxic respiratory failure. This patient was managed suc-
cessfully with combined treatment of interventional
catheterization, extracorporeal membrane oxygenation
(ECMO) support, pulmonary lobectomy, and early initi-
ation of immunotherapy (Figure 1).* Correspondence: dkimura@uthsc.edu
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A 14-year-old African-American female presented with
sudden onset of shortness of breath and palpitations. Her
past history was significant for a recent diagnosis of SLE
when she had presented with complaints of rapid weight
loss (9 kg over 2 months), easy fatiguability, and a malar
facial rash a month back. Her laboratory evaluation was
positive for fluorescent antinuclear antibody (FANA) of
1:360 (speckled pattern), a low white blood cell (WBC)
count of 3,300/mm3, a low hemoglobin count of 3.3 g/dl,
and urine analysis that demonstrated 2+ albumin with 2+
blood. Other pertinent labs included a positive anti-SSA of
311 RU/ml, a positive anti-SSB of 644 RU/ml, and a posi-
tive RPR of 1:8 together with a negative test for treponema
pallidum. These abnormal labs together with the clinical
presentation led to the diagnosis of SLE. She had been
started on hydroxychloroquine and prednisone. She was
seen in the emergency department (ED) on three different
occasions since diagnosis for various non-specific com-
plaints including dry cough, mild hemoptysis, shortness of
breath, and syncope. She was found to be severely anemic
(hemoglobin of 4.1 g/dl) and treated with blood transfu-
sion and iron supplements. A diagnosis of right lower lobe
pneumonia had been made and she was treated with oral
antibiotics.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Consider initiation of ECMO without 
anticoagulation if bleeding persists
Figure 1 Management of severe diffuse alveolar hemorrhage with SLE. Consider initiation of ECMO without anticoagulation if bleeding
persists.
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chest x-ray showed infiltrates and effusion over the right
middle and lower lobes. While in the ED, she developed
worsening tachycardia, tachypnea, and hypotension requir-
ing rapid intubation with a single lumen endotracheal tube
(ETT). Copious bright red blood was seen upon intubation
indicative of massive pulmonary hemorrhage. She was
emergently taken to the catheterization laboratory to locate
and potentially embolize the source of the bleeding. Select-
ive angiography demonstrated the right bronchial artery as
the source of bleeding. However, the anterior spinal artery
was found to branch off the right bronchial artery, just
proximal to the level of the bleeding. Hence, embolization
was deferred due to the potential risk of paraplegia. During
the procedure, the patient developed progressive hypoxic
respiratory failure requiring escalation of support to high-
frequency oscillatory ventilator (HFOV). However, despite a
mean air pressure of 45 cm H2O and addition of inhaled ni-
tric oxide, there was no improvement. Hence, she was
emergently cannulated for venovenous-ECMO. Initially
one double lumen cannula was placed in the right internal
jugular vein; however, the venous flow was not sufficient.
The other cannula was placed in the left femoral vein toachieve the target ECMO flow. The single lumen ETT was
exchanged for a double lumen ETT to protect the non-
bleeding lung. She was transferred to the operation room
on ECMO where she underwent an emergent right upper
and middle pulmonary lobectomy. During procedure, the
entire right lung was noted to be densely consolidated with
a hemorrhagic appearance. Microscopically, the tissue dem-
onstrated diffuse interseptal capillary wall damage with
marked neutrophil infiltration and massive intraalveolar
hemorrhage, and hemosiderin-laden macrophages are
present in all lobes of the right lung. Pathology diagnosis is
pulmonary neutrophilic capillaritis with diffuse parenchyma
hemorrhage.
Following surgery, she was transferred to the cardiac
ICU where she was maintained on venovenous-ECMO
and HFOV due to hypoxia and hemodynamic instability
(Figure 2). To avoid further bleeding, platelet was trans-
fused to keep platelet counts >100,000/μl. Anticoagula-
tion therapy with heparin drip for ECMO was not given
at the beginning. It was started at the lower dosage to
titrate the activated clotting time (ACT) between 140
and 160 s for the first 48 h after the operation, then
increased to keep ACT 180–200 s. During the first week,
Figure 2 Patient chest x-ray. Patient lungs are shown to be clear.
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3 days, which was then reduced to 60 mg every 6 h. In
view of ongoing hemoptysis and potential for further pul-
monary hemorrhage, she was treated with plasmapheresis
while on ECMO with alternate day treatment regimens for
3 cycles. In addition, intravenous immunoglobulin (IVIG)
of 2 g/kg/dose was also administered to minimize the risk
of recurrent pulmonary hemorrhage. A single dose of
750 mg of cyclophosphamide was also administered to
reduce the inflammatory effects of active SLE. Although
she received multiple packed red blood cell, frozen fresh
plasma, and platelet transfusions during her hospital
course, the requirement for blood products declined as
medical treatments for SLE with plasmapheresis and IVIG
were advanced. A respiratory culture of streptococcus viri-
dans was treated with appropriate antibiotics. A chest tube
was placed on day 3 for a left hemothorax. On the fifth
postoperative day, bronchoscopy demonstrated clear airway
without active signs of hemorrhage. The patient was transi-
tioned to a conventional ventilator from the HFOV on
post-op day 7. She was successfully decannulated from
ECMO on day 10. She was extubated on day 18 and dis-
charged home in a stable condition after 57 days of hospital
stay. At the time of discharge, she was comfortably breath-
ing room air without any neurological sequelae. Predis-
charge chest x-ray revealed clear lung fields.
Discussion
Although there is a wide spectrum of pulmonary mani-
festations in SLE, pulmonary hemorrhage occurs in 5 to
10% of pediatric SLE patients with pulmonary involve-
ment. It can present as a chronic low-grade hemorrhage
with few early symptoms, but more frequently it pre-
sents as acute respiratory distress [4]. One type of pul-
monary hemorrhage, DAH, is a rare and life-threateningcomplication of SLE associated with high mortality [5].
DAH may present in the early course of SLE in children
[1] and is associated with high disease activity [6]. Bleed-
ing into the alveolar spaces characterizes the syndrome
of DAH and is due to disruption of the alveolar-capillary
basement membrane caused by injury or inflammation
of the arterioles, venules, or alveolar septal (alveolar wall
or interstitial) capillaries.
Thoracic surgery should be consulted early in the
course of management, and emergency lung resection is
a life-saving procedure if bronchial artery embolization
(BAE) is unsuccessful [7]. With advances in interven-
tional radiology, the number of emergent surgery for
massive hemoptysis has decreased because of associated
morbidity and mortality; however, surgery is indicated
for technically difficult cases of BAE, respiratory or
hemodynamically unstable patients for BAE, and early
or repeated recurrence of hemoptysis after BAE [8,9]. In
general, surgery was not considered as an option for pa-
tients with moderate to severe lung function impair-
ment. However, early initiation of ECMO could improve
oxygen delivery and allow to perform a life-saving sur-
gery as seen in our case [8].
ECMO was used as a rescue therapy for the severe
respiratory failure in DAH secondary to SLE [10].
Anticoagulation therapy with heparin was initially
deferred until hemostasis was achieved, despite a risk
of ECMO circuit thrombosis, since ECMO can be
performed without systemic anticoagulation for short
periods [11,12]. Once hemostasis is achieved, anticoa-
gulation therapy should be initiated to prevent the
thrombosis in the ECMO circuit and oxygenation
membrane. Kolovos et al. reported that eight children
with respiratory failure from pulmonary hemorrhage
were successfully managed with ECMO with continu-
ous heparin drip with the target of ACT 160–180 s
[13]. Currently the ideal target level of anticoagulation
for patients with pulmonary hemorrhage in children is
unknown.
These interventions would not have been successful if
medical treatment against SLE was not initiated as soon
as possible. The main therapy for DAH with SLE in chil-
dren and adults is high-dose methylprednisolone [1]
combined with cyclophosphamide [6] and plasmapher-
esis [5]. The other therapeutic options are rituximab,
IVIG, and mycophenolate mofetil [6]. Plasmapheresis
performed on ECMO has a benefit for sharing vascular
access and has been used for severe pulmonary
hemorrhage due to other autoimmune diseases [14].
Currently there are no therapeutic guidelines for this
life-threatening manifestation of SLE due to the rarity of
this condition. Multi-institutional data collection would
be beneficial for determining the effectiveness of each
therapeutic options for this condition.
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This is the first report of a child with massive hemoptysis
due to SLE requiring ECMO support followed by emer-
gency lobectomy and early initiation of immunotherapy
including plasmapheresis that resulted in a good outcome.
Although ongoing hemorrhage might be considered a
contraindication for ECMO, our case demonstrated that
this is an effective intervention. The successful outcome of
our patient suggests that cases of SLE with DAH unre-
sponsive to conventional therapies can be successfully
treated with combinations of interventional radiology,
ECMO, surgery, and immunotherapy.
Consent
Informed consent was obtained from the family for the pub-
lication of this case report and any accompanying images. A
copy of the written consent is available for review by the
Editor-in-Chief of this journal. We obtained the institutional
review board approval (the University of Tennessee Health
Science Center) for this study including a waiver of the need
for informed consent from the patient.
Abbreviations
DAH: Diffuse alveolar hemorrhage; SLE: Systemic lupus erythematosus;
ECMO: Extracorporeal membrane oxygenation; FANA: Fluorescent antinuclear
antibody; WBC: White blood cell; ED: Emergency department; ETT: Endotracheal
tube; HFOV: High-frequency oscillatory ventilation; ICU: Intensive care unit;
IVIG: Intravenous immunoglobulin; BAE: Bronchial artery embolization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DK and MBM collected the patient data. All authors were involved in the
treatment of the patient. DK drafted the manuscript and obtained approval from
the institutional review board. DK, SaS, ShS, and CKC revised and edited the
manuscript. All authors contributed and approved the final version of the
manuscript.
Author details
1Division of Pediatric Critical Care Medicine, Department of Pediatrics, Le
Bonheur Children’s Hospital/University of Tennessee Health Science Center,
50 N. Dunlap St, TN, Memphis 38103, USA. 2Department of ECMO/Apheresis,
Le Bonheur Children’s Hospital/University of Tennessee Health Science
Center, 50 N. Dunlap St, Memphis, TN, USA. 3Department of Cardiology, Le
Bonheur Children’s Hospital/University of Tennessee Health Science Center,
50 N. Dunlap St, Memphis, TN, USA. 4Department of Pulmonology, Le
Bonheur Children’s Hospital/University of Tennessee Health Science Center,
50 N. Dunlap St, Memphis, TN, USA. 5Department of Pathology, Le Bonheur
Children’s Hospital/University of Tennessee Health Science Center, 50 N.
Dunlap St, Memphis, TN, USA. 6Department of Rheumatology, Le Bonheur
Children’s Hospital/University of Tennessee Health Science Center, 50 N.
Dunlap St, Memphis, TN, USA. 7Department of Cardiovascular Surgery, Le
Bonheur Children’s Hospital/University of Tennessee Health Science Center,
50 N. Dunlap St, Memphis, TN, USA.
Received: 21 November 2014 Accepted: 13 February 2015
References
1. Singla S, Muscal E, Canter D, Deguzman M, Vece T. A79: pulmonary
hemorrhage in pediatric systemic lupus erythematous: clinical course and
outcomes. Arthritis Rheumatol. 2014;66 Suppl 11:S112.
2. Martinez-Martinez MU, Sturbaum AK, Alcocer-Varela J, Merayo-Chalico J,
Gomez-Martin D, Gomez-Banuelos Jde J, et al. Factors associated withmortality and infections in patients with systemic lupus erythematosus with
diffuse alveolar hemorrhage. J Rheumatol. 2014;41:1656–61.
3. Todd DJ, Costenbader KH. Dyspnoea in a young woman with active
systemic lupus erythematosus. Lupus. 2009;18:777–84.
4. Silverman E, Eddy A. Systemic lupus erythematosus, textbook of pediatric
rheumatology. 6th ed. Philadelphia: Saunders; 2011.
5. Erickson RW, Franklin WA, Emlen W. Treatment of hemorrhagic lupus
pneumonitis with plasmapheresis. Semin Arthritis Rheum. 1994;24:114–23.
6. Martinez-Martinez MU, Abud-Mendoza C. Diffuse alveolar hemorrhage in
patients with systemic lupus erythematosus. Clinical manifestations,
treatment, and prognosis. Reumatol Clin. 2014;10:248–53.
7. Knott-Craig CJ, Oostuizen JG, Rossouw G, Joubert JR, Barnard PM.
Management and prognosis of massive hemoptysis. Recent experience with
120 patients. J Thorac Cardiovasc Surg. 1993;105:394–7.
8. Sakr L, Dutau H. Massive hemoptysis: an update on the role of
bronchoscopy in diagnosis and management. Respiration. 2010;80:38–58.
9. Fartoukh M, Khalil A, Louis L, Carette MF, Bazelly B, Cadranel J, et al. An
integrated approach to diagnosis and management of severe haemoptysis in
patients admitted to the intensive care unit: a case series from a referral centre.
Respir Res. 2007;8:11.
10. Pacheco Claudio C, Charbonney E, Durand M, Kolan C, Laskine M.
Extracorporeal membrane oxygenation in diffuse alveolar hemorrhage
secondary to systemic lupus erythematosus. J Clin Med Res. 2014;6:145–8.
11. Ahmed SH, Aziz T, Cochran J, Highland K. Use of extracorporeal membrane
oxygenation in a patient with diffuse alveolar hemorrhage. Chest.
2004;126:305–9.
12. Alexander GR. A retrospective review comparing the treatment outcomes of
emergency lung resection for massive haemoptysis with and without
preoperative bronchial artery embolization. Eur J Cardiothorac Surg.
2014;45:251–5.
13. Kolovos NS, Schuerer DJ, Moler FW, Bratton SL, Swaniker F, Bartlett RH, et al.
Extracorporal life support for pulmonary hemorrhage in children: a case series.
Crit Care Med. 2002;30:577–80.
14. Tandon M, Reynolds HN, Borg U, Habashi NM, Cottingham C. Life-threatening
acute systemic lupus erythematosus: survival after multiple extracorporeal
modalities: a place for the multipotential extracorporeal service. ASAIO J.
2000;46:146–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
